Stirling, Scotland, 19th June 2017 – eClinicalHealth Limited, a cloud-based remote clinical research technology company, releases a white paper on the key considerations for designing and implementing direct-to-patient remote clinical research.
“The challenges associated with conducting and managing today’s larger, multinational Phase III clinical trials have never been greater. There has been a dramatic increase in costs and trial complexity in recent years. Biopharmaceutical companies are exploring new approaches to conduct studies that will have a significant impact on cost savings, timelines, improve overall patient recruitment and retention, and also create a more meaningful patient experience,” says Abbe Steel, MSc, CEO HealthiVibe, who helped author the Whitepaper.
Karl Landert, MSc, CEO of eClinicalHealth comments “Technological advances have reached a level of maturity that allows biopharmaceutical companies to start considering implementing more direct-to-patient clinical trial designs. While no single study design and conduct strategy should be taken as the solution to the financial and operational burdens of clinical development, the clinical research industry is poised to begin introducing a more patient-centered clinical trial research model. Such models also lend themselves to designing and running an increasing number of large-scale post-approval studies that provide real world evidence (RWE).”
As with any novel approach to clinical trials, there are many factors that must be evaluated. This whitepaper outlines what is involved in the design and implementation of virtual clinical trials, how they can be used to engage hard to reach patient populations, and includes a discussion of important operational, scientific and technological considerations and solutions. Download the white paper at no charge HERE.
Headquartered in Scotland, eClinicalHealth Limited, developers of the ClinpalTM remote research platform, was founded in 2012 to provide innovative clinical trial solutions. The company is committed to leading open and collaborative innovation discussions about patient-centric clinical trial processes and technology with pharmaceutical companies, CROs and other service and technology providers.